Drug
JNJ-18038683
JNJ-18038683 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_2
2
67%
Ph not_applicable
1
33%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (66.7%)
N/A1 (33.3%)
Trials by Status
completed267%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients
NCT02466685
unknownnot_applicable
Imaging 5HT7 Antagonist Effects in Bipolar Disorder
NCT03633357
completedphase_2
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
NCT00566202
Clinical Trials (3)
Showing 3 of 3 trials
NCT02466685Phase 2
Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients
NCT03633357Not Applicable
Imaging 5HT7 Antagonist Effects in Bipolar Disorder
NCT00566202Phase 2
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3